CLAIMS

1. A pharmaceutical composition including a combination of (a) at least one hyperlipidemic agent selected from the group consisting of a fibrate compound and a hydroxymethylglutaryl-CoA reductase inhibitor with (b) an α-glucosidase inhibitor, wherein the pharmaceutical is

(i) a pharmaceutical composition comprising the hyperlipidemic agent (a) and the α-glucosidase inhibitor (b), or

(ii) a pharmaceutical combination including a pharmaceutical component comprising the hyperlipidemic agent (a) and a pharmaceutical component comprising the α-glucosidase inhibitor (b).

2. A pharmaceutical composition according to claim 1, wherein the fibrate compound comprises at least one member selected from the group consisting of fenofibrate, bezafibrate, clinofibrate, clofibrate, simfibrate, fenofibric acid, and gemfibrozil, or a salt thereof.

3. A pharmaceutical composition according to claim 1, wherein the fibrate compound comprises at least one member selected from the group consisting of fenofibrate, and bezafibrate, or a salt thereof.

4. A pharmaceutical composition according to claim 1, wherein the hydroxymethylglutaryl-CoA reductase inhibitor comprises at least one statin compound selected

from the group consisting of pravastatin, simvastatin, fluvastatin, atorvastatin, lovastatin, cerivastatin, pitavastatin, and rosvastatin, or a salt thereof.

5. A pharmaceutical composition according to claim 1, wherein the hydroxymethylglutaryl-CoA reductase inhibitor comprises at least one statin compound selected from the group consisting of pravastatin, and atorvastatin, or a salt thereof.

6. A pharmaceutical composition according to claim 1, wherein the α-glucosidase inhibitor (b) comprises at least one member selected from the group consisting of voglibose, acarbose, miglitol, and emiglitate, or a salt thereof.

7. A pharmaceutical composition according to claim 1, wherein the α-glucosidase inhibitor (b) comprises at least one member selected from the group consisting of voglibose and acarbose.

8. A pharmaceutical composition according to claim 1, wherein the proportion of the α-glucosidase inhibitor (b) is 0.001 to 50 parts by weight relative to 100 parts by weight of the hyperlipidemic agent (a).

9. A pharmaceutical composition according to claim 1, wherein the proportion of the α-glucosidase inhibitor (b) is 0.01 to 10 parts by weight relative to 100 parts by weight of the hyperlipidemic agent (a).

10. A pharmaceutical composition including a combination of fenofibrate and voglibose, which is

(i) a pharmaceutical composition comprising the fenofibrate and the voglibose, or

(ii) a pharmaceutical combination including a pharmaceutical component comprising the fenofibrate and a pharmaceutical component comprising the voglibose.

11. A pharmaceutical composition according to claim 1 or 10, which is an agent for the prophylaxis or treatment of metabolic syndrome.

12. A pharmaceutical composition according to claim 1 or 10, which is an agent for the prophylaxis or treatment of at least one symptom selected from the group consisting of hyperlipemia, diabetes, diabetes complications, a symptom of hyperglycemia after a meal in diabetics, impaired glucose tolerance (IGT), decrease of glucose tolerance, hypertension, hyperinsulinemia, hyperammonemia, obesity or a complication thereof, fatty liver, and hepatitis.

13. A pharmaceutical composition according to claim 1 or 10, which is an agent for the prophylaxis or treatment of hyperlipemia.

14. A pharmaceutical composition according to claim 1 or 10, which is an agent for the prophylaxis or treatment of at least one symptom selected from the group consisting of diabetes, diabetes complications and a symptom of hyperglycemia after a meal in diabetics.

15. A pharmaceutical composition according to claim 1, which is

(i) a pharmaceutical preparation comprising (a) a hyperlipidemic agent and (b) an α-glucosidase inhibitor, or

(ii) a pharmaceutical combination including a pharmaceutical preparation comprising the hyperlipidemic agent (a) and a pharmaceutical preparation comprising the α-glucosidase inhibitor (b).

16. Use of (a) at least one hyperlipidemic agent selected from the group consisting of a fibrate compound and a hydroxymethylglutaryl-CoA reductase inhibitor, and (b) an α-glucosidase inhibitor for preparing a pharmaceutical preparation.

17. A pharmaceutical composition reducing a side effect or dose of an α-glucosidase inhibitor, which includes a combination of (a) at least one hyperlipidemic agent selected from the group consisting of a fibrate compound and a hydroxymethylglutaryl-CoA reductase inhibitor and (b) an α-glucosidase inhibitor, wherein the pharmaceutical composition is

(i) a pharmaceutical composition comprising the hyperlipidemic agent (a) and the α-glucosidase inhibitor (b), or

(ii) a pharmaceutical combination including a pharmaceutical component comprising the hyperlipidemic agent (a) and a pharmaceutical component comprising the α-glucosidase inhibitor (b).

18. A method for preventing or treating at least

one symptom selected from the group consisting of metabolic syndrome, hyperlipemia, diabetes, diabetes complications, a symptom of hyperglycemia after a meal in diabetics, impaired glucose tolerance (IGT), decrease of glucose tolerance, hypertension, hyperinsulinemia, hyperammonemia, obesity or a complication thereof, fatty liver, and hepatitis; wherein the method comprises

administering (a) at least one hyperlipidemic agent selected from the group consisting of a fibrate compound and a hydroxymethylglutaryl-CoA reductase inhibitor and (b) an α-glucosidase inhibitor to human or non-human animals to prevent or treat the symptom.